EyePoint Pharmaceuticals Inc (EYPT)

[abeta]

Q4 2023
Regeneron reported $1.46 billion in U.S. sales for Eylea and Eylea HD, including $123 million from Eylea HD.

Q1 2023
Regeneron reported a 6% drop in Eylea sales compared to the same period in 2022.

Q2 2023
Regeneron reported $1.50 billion in U.S. sales for Eylea.

2023
Regeneron reported $5.89 billion in U.S. sales for Eylea, including $166 million from Eylea HD.
The aflibercept market is expected to grow from $8,343.15 million in 2022 to $13,911.94 million by 2030. Factors that may contribute to this growth include:
Increasing prevalence of wet macular degeneration, diabetic retinopathy, and visual impairment from diabetic macular edema
Advancements in treatment therapies